Jounce Therapeutics Short Interest Ratio and Short Volume

Short interest is the volume of Jounce Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 15th, investors have sold 1,320,000 shares of JNCE short. 7.99% of Jounce Therapeutics' shares are currently sold short. View details.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Jounce Therapeutics currently has a short interest ratio of 1.0.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.99% of Jounce Therapeutics' floating shares are currently sold short.

Jounce Therapeutics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 1,320,000 shares, a decline of 38.3% from the previous total of 2,140,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Jounce Therapeutics currently has issued a total of 34,068,000 shares. Some of Jounce Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jounce Therapeutics currently has a public float of 16,520,000 shares.

7.99% of Jounce Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Jounce Therapeutics: Compugen Ltd. (0.00%), Regenxbio Inc (13.50%), Adaptimmune Therapeutics PLC - (0.00%), Translate Bio Inc (0.00%), Atara Biotherapeutics Inc (0.00%), Alector Inc (15.06%), Adverum Biotechnologies Inc (0.00%), Replimune Group Inc (3.52%), Vericel Corp (0.00%), and Krystal Biotech Inc (12.43%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications Inc ($5.17 billion), Aon PLC ($3.57 billion), ViacomCBS Inc. ($3.01 billion), Clorox Co ($2.91 billion), Charles Schwab Co. ($2.80 billion), Mercadolibre Inc ($2.33 billion), Analog Devices, Inc. ($2.14 billion), Kroger Co ($1.99 billion), Moderna Inc ($1.96 billion), and Simon Property Group Inc ($1.80 billion). View all of the most shorted stocks.

Short selling JNCE is an investing strategy that aims to generate trading profit from Jounce Therapeutics as its price is falling. Jounce Therapeutics' stock is trading down $0.14 today. To short Jounce Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Jounce Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Jounce Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JNCE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JNCE, twice per month. The most recent reporting period available is September, 15 2020.